SNIPR: Turning CRISPR into a microbiome suicide
Occupying the intersection of the microbiome and CRISPR, SNIPR treats disease by using gene editing to alter gut bacterial populations
SNIPR is using CRISPR to target specific bacteria to fight infection or modulate the immune system.
Growing interest in CRISPR for mammalian cells and microbiome-focused therapeutics led the company's co-founders, Christian Grøndahl, Morten Sommer and Jasper Clube, to explore the possibility of using bacteria's own endogenous CRISPR-associated (Cas) proteins to cut its DNA, CEO Grøndahl told BioCentury.
The company was incubated at the Novo Nordisk Foundation Center for Biosustainability at Technical University of Denmark